A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
